PAH therapies improved hemodynamic parameters and reduced NT-proBNP levels in PH-ILD patients, indicating potential benefits. Precision medicine could help identify PH-ILD patients who may benefit ...

The FDA is poised to issue a final decision on the approval and marketing of Yutrepia, an inhaled dry powder formulation of ...

A new study from Thailand shows that a rapid peak in skin thickness progression in systemic sclerosis patients may predict ...

YUTREPIA received tentative FDA approval for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) but must await the end of ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and ...

These factors contribute to the analyst’s projection of TPIP achieving over $2 billion in peak sales opportunities within the PH-ILD and PAH markets. The enthusiastic feedback from Key Opinion ...

Observations to date have demonstrated tolerability and titratability of YUTREPIA in PH-ILD patients that is consistent with observations from the prior INSPIRE study in PAH patients. Liquidia ...